Javier Rejas

Dr. Javier Rejas

Health Economics and Outcomes Research Department, Pfizer, SLU, Alcobendas (Madrid), Spain.
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
JGJavier García-Campayo
Javier García-Campayo
EZEnric Zamorano
Enric Zamorano
MRMiguel A Ruiz
Miguel A Ruiz
APAntonio Pardo
Antonio Pardo
MPMaria Perez-Paramo
Maria Perez-Paramo
JRJavier Rejas
Javier Rejas
Generalized anxiety disorder (GAD) is a prevalent mental health condition which is underestimated worldwide. This study carried out the cultural adaptation into Spanish of the 7-item self-administered GAD-7 scale, which is used to identify probable patients with GAD.

4 December 2007 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
CPConcepcion Perez
Concepcion Perez
RGRafael Galvez
Rafael Galvez
SHSilvia Huelbes
Silvia Huelbes
JIJoaquin Insausti
Joaquin Insausti
DBDidier Bouhassira
Didier Bouhassira
JRJavier Rejas
Javier Rejas
This study assesses the validity and reliability of the Spanish version of DN4 questionnaire as a tool for differential diagnosis of pain syndromes associated to a neuropathic (NP) or somatic component (non-neuropathic pain, NNP).

23 May 2006 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
PCPILAR CARRASCO-GARRIDO
PILAR CARRASCO-GARRIDO
JMJavier de Miguel-Díez
Javier de Miguel-Díez
JRJavier Rejas
Javier Rejas
ACAntonio Martín Centeno
Antonio Martín Centeno
EVElena Gobartt Vázquez
Elena Gobartt Vázquez
RGRodrigo Jiménez Garcia
Rodrigo Jiménez Garcia
Background: COPD is currently the fourth cause of morbidity and mortality in the developed world. Patients with COPD experience a progressive deterioration and disability, which lead to a worsening in their health-related quality of life (HRQoL). The aim of this work is to assess the Health-Related Quality of Life (HRQoL) of patients with stable COPD followed in primary care and to identify possible predictors of disease.Methods: It is a multicenter, epidemiological, observational, descriptive study. Subjects of both sexes, older than 40 years and diagnosed of COPD at least 12 months before starting the study were included. Sociodemographic data, severity of disease, comorbidity, and use of health resources in the previous 12 months were collected. All patients were administered a generic quality-of-life questionnaire, the SF-12, that enables to calculate two scores, the physical (PCS-12) and the mental (MCS-12) component summary scores.Results: 10,711 patients were evaluated (75.6% men, 24.4% women), with a mean age of 67.1 years (SD 9.66). The mean value of FEV1was 35.9 ± 10.0%. Mean PCS-12 and MCS-12 scores were 36.0 ± 9.9 and 48.3 ± 10.9, respectively. Compared to the reference population, patients with COPD had a reduction of PCS-12, even in mild stages of the disease. The correlation with FEV1was higher for PCS-12 (r = 0.38) than for MCS-12 (r = 0.12). Predictors for both HRQoL components were sex, FEV1, use of oxygen therapy, and number of visits to emergency rooms and hospital admissions. Other independent predictors of PCS-12 were age, body mass index and educational level.Conclusion: Patients with stable COPD show a reduction of their HRQoL, even in mild stages of the disease. The factors determining the HRQoL include sex, FEV1, use of oxygen therapy, and number of visits to emergency rooms and hospital admissions.

1 April 2007 in European journal of pain
Verified
Journal Article
Closed access
JRJavier Rejas
Javier Rejas
MRMaría Victoria Ribera
María Victoria Ribera
MRManuel Ruiz
Manuel Ruiz
XMXavier Masrramón
Xavier Masrramón

1 January 2012 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
JGJavier García-Campayo
Javier García-Campayo
EZEnric Zamorano
Enric Zamorano
MRMiguel A Ruiz
Miguel A Ruiz
MPMaría Pérez-Páramo
María Pérez-Páramo
VLVanessa López-Gómez
Vanessa López-Gómez
JRJavier Rejas
Javier Rejas
To psychometrically validate the Spanish version of the self-administered 2-item GAD-2 scale for screening probable patients with generalised anxiety disorder (GAD). The GAD-2 was self-administered by patients diagnosed with GAD according to DSM-IV criteria and by age- and sex-matched controls who were recruited at random in mental health and primary care centres. Criteria validity was explored using ROC curve analysis, and sensitivity, specificity and positive and negative predictive values were determined for different cut-off values. Concurrent validity was also established using the HAM-A, HADS, and WHODAS II scales. The study sample consisted of 212 subjects (106 patients with GAD) with a mean age of 50.38 years (SD = 16.76). No items of the scale were left blank. Floor and ceiling effects were negligible. No patients with GAD had to be assisted to complete the questionnaire. Reliability (internal consistency) was high; Cronbach's α = 0.875. A cut-off point of 3 showed adequate sensitivity (91.5%) and specificity (85.8%), with a statistically significant area under the curve (AUC = 0.937, p < 0.001), to distinguish GAD patients from controls. Concurrent validity was also high and significant with HAM-A (0.806, p < 0.001), HADS (anxiety domain, 0.825, p < 0.001) and WHO-DAS II (0.642, p < 0.001) scales. The Spanish version of the GAD-2 scale has been shown to have appropriate psychometric properties to rapidly detect probable cases of GAD in the Spanish cultural context under routine clinical practice conditions.